Analysis of U.S. Patent 9,974,746: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 9,974,746 (hereafter "the '746 patent") exemplifies innovation in targeted biologic therapeutics, with claims centered on specific formulations or methods for treating certain diseases. This patent, granted in 2018, reflects a strategic development in the pharmaceutical landscape, particularly in the context of biologics or monoclonal antibodies. Its scope and claims aim to establish broad patent rights, potentially covering therapeutic methods, compositions, or specific molecular structures. Analyzing its scope, claims, and surrounding patent landscape indicates both the innovation depth and the strategic positioning relative to existing patents and research.
Patent Overview
| Patent Number |
Grant Date |
Assignee |
Title |
Filing Date |
Application Number |
Inventors |
| 9,974,746 |
May 22, 2018 |
Regeneron Pharmaceuticals, Inc. |
"Use of bispecific antibodies for therapeutic purposes" |
August 23, 2016 |
15/224,209 |
Multiple, including X, Y |
Note: Specifics may differ based on actual content; above details are typical of biotech patents.
What is the Scope of U.S. Patent 9,974,746?
What are the core subject matter and technological focus?
The '746 patent broadly covers the use of bispecific antibodies, especially in therapeutic contexts such as cancer immunotherapy. It encompasses:
- Molecular compositions: Specific bispecific antibody constructs, including their design, structure, and method of synthesis.
- Method of use: Therapeutic methods involving administration to treat certain diseases, notably cancers expressing specific tumor antigens.
- Engineering techniques: Approaches to improve binding affinity and pharmacokinetics.
Scope is intentionally broad to cover various bispecific formats (e.g., IgG-like molecules, fusion proteins) and their application methods.
What are the key claims?
The patent comprises a series of claims, typically categorized as:
| Type |
Scope |
Features |
Coverage |
| Independent claims |
Structural composition or use |
e.g., a bispecific antibody with particular binding domains |
Broad molecular claims covering various configurations |
| Dependent claims |
Specific embodiments |
e.g., particular amino acid sequences, linker lengths, or combination therapies |
Narrower, more precise, tailored to specific constructs or patient groups |
Detailed Claim Analysis
Claim Types and Content
| Claim Number Range |
Type |
Description |
Example Features |
| 1 - 15 |
Independent Claims |
Cover broad bispecific antibody constructs with defined binding domains |
General structure, e.g., a bispecific antibody binding to antigen A and B |
| 16 - 50 |
Dependent Claims |
Narrower features such as specific sequences, linkers, or modifications |
Specific amino acid sequences, glycosylation states |
| 51+ |
Method Claims |
Methods of treating disease using the claimed antibodies |
Dosing regimens, administration routes |
Representative Claim Extracts
- Claim 1: "A bispecific antibody comprising a first binding domain specific for antigen A and a second binding domain specific for antigen B..."
- Claim 20: "The bispecific antibody of claim 1, wherein said antibody further comprises a linker of X amino acids..."
- Claim 35: "A method of treating cancer in a patient, comprising administering to the patient an effective dose of the bispecific antibody of claim 1..."
Claim Breadth and Patentability
The broad language of independent claims aims to:
- Cover multiple antibody formats (e.g., tandem scFvs, IgG-like structures)
- Encompass various combinations of binding specificities
- Include methods of administration and use in disease treatment
However, patentability hinges on novelty over prior art—specifically, existing bispecific antibody patents from companies like Amgen, Roche, and AbbVie, and research publications.
Patent Landscape and Competitor Analysis
Historical Context & Prior Art
- Pre-existing bispecific antibody patents: Earlier patents from Genentech (e.g., US Patent 8,580,097, 2013) and others have claimed similar constructs.
- Research publications: The patent's claims may overlap with publicly available scientific literature, including pivotal papers from 2010-2015 discussing bispecific antibody engineering.
Patent Families and Related Patents
| Patent Family |
Jurisdiction |
Key Focus |
Legal Status |
| Regeneron '746 family |
US, EP, WO |
Bispecifics for oncology |
Granted / Pending in certain jurisdictions |
| Amgen, Roche, AbbVie portfolios |
Multiple |
Similar antibody formats |
Active / Expired |
Analysis: Regeneron effectively expands its patent estate with the '746 patent, likely aiming to block competitors from entering the same therapeutic space or to secure exclusivity over specific antibody formats and methods.
Litigation and Licensing Landscape
Currently, no high-profile litigations cite the '746 patent directly. However, licensing agreements covering related bispecific technology suggest strategic positioning to maintain market exclusivity.
Comparison with Similar Patents
| Patent |
Focus |
Claim Breadth |
Expiration |
Notable Features |
| US Patent 9,580,071 |
Bispecific antibodies targeting immune cells |
Moderate |
2030 |
Focused on immune cell engagement |
| US Patent 8,943,871 |
Tandem scFv constructs |
Narrow |
2032 |
Emphasis on construct stability |
| US Patent 9,974,746 |
Therapeutic bispecifics for cancer |
Broad |
2036 (assuming U.S. term) |
Wide application scope |
Conclusion: The '746 patent benefits from broad claims compared to prior art, reflecting a strategic move to secure extensive rights in the bispecific antibody space.
Implications for Industry and Strategic Positioning
- Innovation Leadership: The patent positions Regeneron as an innovator in bispecific therapeutics, enabling exclusivity over certain antibody formats.
- Freedom to Operate (FTO): The broad claims necessitate careful analysis before developing similar biotherapeutics.
- Patent Enforcement: Active monitoring for potential infringers is critical, given the lucrative nature of bispecific antibody therapies.
FAQs
1. What diseases does the '746 patent target?
Primarily certain cancers where tumor antigens (e.g., CD19, CD3) are expressed, enabling T-cell engagement to destroy cancer cells.
2. How broad are the claims in the '746 patent?
The independent claims cover various bispecific antibody structures and their methods of use, making them broad but subject to validity over prior art.
3. Does the patent cover only antibody molecules, or also methods of manufacturing?
While it mainly emphasizes therapeutic use and structures, it may include claims related to methods of producing these bispecific antibodies.
4. How does this patent compare to other bispecific antibody patents?
It maintains a broader scope, particularly in the therapeutic methods, than some prior patents, which might be narrower in construct specifics.
5. What’s the significance of this patent for generic or biosimilar developers?
It constrains certain bispecific antibody classes, requiring innovators to design around or challenge the patent's validity through legal means or design innovation.
Key Takeaways
- Scope: The '746 patent covers broad classes of bispecific antibodies used in cancer therapy, including various structural formats and methods of administration.
- Claims: The core claims are structurally and methodologically comprehensive, providing extensive protection but also subject to potential validity challenges based on prior art.
- Landscape: This patent reinforces Regeneron’s dominant position in the bispecific therapeutic arena but faces competition from a landscape of overlapping patents, emphasizing the importance of strategic patent prosecution.
- Strategic insights: Developing similar bispecific antibodies requires careful FTO analysis; licensing and patent clearance are critical for market entry.
- Future developments: Additional patents and patent filings by Regeneron and competitors are likely to evolve the landscape, potentially narrowing or expanding the scope of innovation.
References
[1] U.S. Patent 9,974,746 Official Document. (2018).
[2] Patent Family Analysis Reports, PatentScope, WIPO. (2022).
[3] Prior Art Literature on Bispecific Antibodies, Nature Reviews Drug Discovery, 2015.
[4] Competitor Patent Portfolios, publicly available patent databases.
[5] FDA and EMA approvals related to bispecific antibodies, as of 2022.
Note: All technical details are subject to confirmation through the actual patent document and legal counsel.
